Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“47”
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Acquisition of lymphokine-producing phenotype by CD4+ T cells
Seder, R. A., & Paul, W. E. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.003223 · Cited by 1,557
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“…was demonstrated when it was shown that the systemic administration of interferon (cid:1) caused exacerbations in patients with relapsing-remitting MS. 42 Numerous approved and experimental MS pharmaco-therapies have been shown to promote a shift or deviation to a T H 2 cytokine profile.”
BackgroundBabbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898 · cited 1×
“41 The clinical significance of this cytokine in MS pathogenesis was demonstrated when it was shown that the systemic administration of interferon (cid:1) caused exacerbations in patients with relapsing-remitting MS. 42 Numerous approved and experimental MS pharmaco-therapies have been shown to…”
BackgroundAcute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 1×
“The concept of epitope spreading emerged in the early 1990s to describe 2 phenomena: (1) diversity at the level of the T-cell receptor V gene (variable) use and ( 2 ) cellular and humeral immune response diversification from a single to numerousantigenicdeterminants.31Epitopespreadingisnot necessarily a pathogenic imm…”
BackgroundDendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829 · cited 3×
“75,76 Large-scale robotic sequencing of messenger RNA from complementary DNA libraries derived from MS brain plaques and gene microarray analysis of transcripts from MS lesions of various types 75,76 have been performed by several groups.”
BackgroundMethodSelf-citationExperimental Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient Mice
Wolf, S. D., Dittel, B. N., Hardardottir, F., & Janeway, C. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2271 · Cited by 699
Stys, P., Waxman, S., & Ransom, B. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00430.1992 · Cited by 662
Self-citationKappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Self-citationAstrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions
Ambrosini, E., Remoli, M. E., Giacomini, E., Rosicarelli, B., Serafini, B., Lande, R., Aloisi, F., & Coccia, E. M. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000173893.01929.fc · Cited by 161
Cited by
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
“Disability in patients with MS is caused by incomplete recovery from inflammatory relapses, gliotic changes, and progressive irreversible neurodegeneration.(5,10) Accordingly, the degree of disability in MS reflects a balance between damage to the CNS and the extent to which this is countered by endogenous repair proc…”
BackgroundSelf-citationDisruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334
Optical coherence tomography: a window into the mechanisms of multiple sclerosis
Frohman, E. M., Fujimoto, J. G., Frohman, T. C., Calabresi, P. A., Cutter, G., & Balcer, L. J. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0950 · Cited by 326
Self-citationNeurological Benefits of Omega-3 Fatty Acids
Dyall, S. C., & Michael-Titus, A. T. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8036-z · Cited by 311
Kapoor, R., Furby, J., Hayton, T., Smith, K. J., Altmann, D. R., Brenner, R., Chataway, J., Hughes, R. A., & Miller, D. H. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70131-9 · Cited by 268
Metadata
- Authors
- Frohman, E. M., Filippi, M., Stuve, O., Waxman, S. G., Corboy, J., Phillips, J. T., Lucchinetti, C., Wilken, J., Karandikar, N., Hemmer, B., Monson, N., De Keyser, J., Hartung, H., Steinman, L., Oksenberg, J. R., Cree, B. A. C., Hauser, S., & Racke, M. K.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-01
- Volume
- 62
- Issue
- 9
- Pages
- 1345
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2156308848
- Cited by
- 106
- References
- 14
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.